EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Synergistic effects of Cyp51 isozyme-specific azole antifungal agents on fungi with multiple cyp51 isozyme genes

Masaki Ishii iD, Kazuki Ishikawa iD, Kazuhiro Mikami, Koji Ichinose iD, Atsushi Miyashita iD, Takashi Yaguchi iD, Tsuyoshi Yamada iD, Shinya Ohata iD

Antimicrobial Agents and Chemotherapy · 2025

DOI: 10.1128/aac.00598-25 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Antimicrobial Agents and Chemotherapy, 2025. Verfasst von Masaki Ishii und 7 weiteren Autor:innen. Beteiligte Einrichtung: Research Institute of Pharmaceutical Sciences, Faculty of Pharmacy, Musashino University, Nishitokyo, Japan. Hauptthemen laut MEDLINE: Antifungal Agents, Azoles, Fungal Proteins, Cytochrome P450 Family 51. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 33 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Takeda Science Foundation, DAIGAKUTOKUBETSU KENKYUHI Grant from Musashino University, JSPS KAKENHI Grant.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Pathogenic fungi pose significant societal challenges due to limited therapeutic targets resulting from the eukaryotic nature of fungi. This limitation emphasizes the importance of enhancing susceptibility to inhibitors of Cyp51, a crucial enzyme in ergosterol biosynthesis targeted by azole antifungals. In Cyp51 isozyme deletion strains (Δ cyp51A and Δ cyp51B ) of Trichophyton rubrum , the predominant dermatophyte species, we found that Cyp51B is essential for basal mycelial growth, while Cyp51A functions as an inducible isozyme associated with azole tolerance. Based on these differential functions, we hypothesized that each isozyme would show distinct susceptibility to azole antifungals. Our study demonstrated that most azoles exhibited increased antifungal activity against Δ cyp51A , while select agents demonstrated increased antifungal activity against Δ cyp51B . Remarkably, fluconazole, sulconazole, and imazalil exhibited relatively increased activity against Δ cyp51A , whereas prochloraz demonstrated increased activity against Δ cyp51B . Combining these isozyme-selective agents exerted synergistic effects against the wild-type strain and the parent ku80 -knockout strain but not against individual Cyp51 knockout mutants. Our data revealed that the two Cyp51 isozymes can be selectively inhibited by different azole antifungals, resulting in a synergistic effect when combined. This synergistic effect was also observed on another fungal species, Aspergillus welwitschiae , which also has two Cyp51 isozymes. These data demonstrate that combining azole antifungals with different Cyp51 isozyme selectivities exerts synergistic effects against fungi possessing multiple Cyp51 isozymes. These findings advance antifungal therapeutic strategies by demonstrating that the combination of antifungals with different Cyp51 isozyme selectivities offers a promising approach for treating fungal infections, opening new avenues for isozyme-specific drug development.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antifungal AgentsAzolesFungal ProteinsCytochrome P450 Family 51Sterol 14-DemethylaseMicrobial Sensitivity TestsIsoenzymesDrug SynergismArthrodermataceae

Stichwörter der Autor:innen

AspergillusCyp51 isozymesCyp51ATrichophyton rubrumantifungal resistanceazole antifungalazole synergismdermatophyte

Substanzen

Antifungal AgentsAzolesIsoenzymesFungal ProteinsCytochrome P450 Family 51Sterol 14-Demethylase

Autor:innen und Institutionen

  • Research Institute of Pharmaceutical Sciences, Faculty of Pharmacy, Musashino University, Nishitokyo, Japan.
  • Faculty of Pharmaceutical Sciences, Teikyo Heisei University, Tokyo, Japan.
  • Graduate School of Medical Care and Technology, Teikyo University, Hachioji, Japan.
  • Teikyo University Institute of Medical Mycology (TIMM), Hachioji, Japan.
  • Medical Mycology Research Center, Chiba University, Chiba, Japan.
  • Asia International Institute of Infectious Disease Control, Teikyo University, Tokyo, Japan.

ORCID-Profile: Masaki Ishii, Kazuki Ishikawa, Koji Ichinose, Atsushi Miyashita, Takashi Yaguchi, Tsuyoshi Yamada, Shinya Ohata

Förderung

  • Takeda Science Foundation
  • DAIGAKUTOKUBETSU KENKYUHI Grant from Musashino University
  • JSPS KAKENHI Grant

Zitieren

APA

Ishii, M., Ishikawa, K., Mikami, K., Ichinose, K., Miyashita, A., Yaguchi, T., Yamada, T., & Ohata, S. (2025). Synergistic effects of Cyp51 isozyme-specific azole antifungal agents on fungi with multiple cyp51 isozyme genes. Antimicrobial Agents and Chemotherapy. https://doi.org/10.1128/aac.00598-25

Vancouver

Ishii M, Ishikawa K, Mikami K, Ichinose K, Miyashita A, Yaguchi T, et al. Synergistic effects of Cyp51 isozyme-specific azole antifungal agents on fungi with multiple cyp51 isozyme genes. Antimicrobial Agents and Chemotherapy. 2025. doi:10.1128/aac.00598-25

BibTeX
@article{Ishii2025,
  author = {Ishii, Masaki and Ishikawa, Kazuki and Mikami, Kazuhiro and Ichinose, Koji and Miyashita, Atsushi and Yaguchi, Takashi and Yamada, Tsuyoshi and Ohata, Shinya},
  title = {Synergistic effects of Cyp51 isozyme-specific azole antifungal agents on fungi with multiple cyp51 isozyme genes},
  journal = {Antimicrobial Agents and Chemotherapy},
  year = {2025},
  doi = {10.1128/aac.00598-25}
}
Kostenlos starten →